critical decisions at the interface between the preclinical and clinical, combining our unsurpassed neuroscience and Parkinson’s expertise with an industry-leading range of rodent and NHP models to design the best-tailored program for any potential therapeutic.

With offices and state-of-the-art facilities in Toronto and Suzhou, Atuka has been involved in the preclinical evaluation of more than 300 potential therapeutics, predominantly in Parkinson’s disease, of which more than 30 have progressed to clinical trials—a level of experience without equal in our field globally.